20
Participants
Start Date
August 23, 2019
Primary Completion Date
September 30, 2025
Study Completion Date
September 30, 2025
Refixia®
Patients will be treated with commercially available Refixia® according to routine clinical practice at the discretion of the treating physician
Novo Nordisk Investigational Site, Søborg
Nagoya University Hospital_Blood Transfusion, Aichi
Chiba University Hospital_Diabetes, Metabolism and Endocrinology, Chiba-shi, Chiba
Hyogo prefectural kobe children's hospital, Hyōgo
Tokyo Medical University Ibaraki Medical Center_Ibaraki, Ibaraki
St. Marianna University School of Medicine Hospital_Pediatrics, Kanagawa
Kitasato University Hospital, Kanagawa
Hospital of the University of Occupational And Environmental Health Japan, Pediatrics, Kitakyusyu-shi, Fukuoka
Gunma University Hospital, Dept. of Hematology, Maebashi-shi, Gunma
Naha City Hospital, Naha-shi, Okinawa
Nara Medical University Hospital_Pediatrics, Nara
The Hospital of Hyogo College of Medicine_Haematology, Nishinomiya-shi, Hyogo
Saitama Children's Med Centre_Hematology-Oncology, Saitama
Tokushima Red Cross Hospital_Pediatrics, Tokushima
Tokyo Medical Univ. Hospital_Laboratory Medicine, Tokyo
Ogikubo Hospital_Tokyo, Tokyo
Ishiyama Clinic, Yamagata
Lead Sponsor
Novo Nordisk A/S
INDUSTRY